- dBET1
-
- $0.00 / 1mg
-
2025-02-12
- CAS:1799711-21-9
- Min. Order: 1mg
- Purity: 98%min
- Supply Ability: 500mg
- dBET1
-
- $7.00 / 1KG
-
2020-01-14
- CAS:1799711-21-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| Product Name: | dBET1 | | Synonyms: | dBET1;DBET1;DBET-1 ;DBET 1;CS-2706;6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-, (6S)-;N-(4-{2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0,2,6]trideca-2 (6),4,7,10,12-pentaen-9-yl]acetamido}butyl)-2-{[2-(
2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-i soindol-4-yl]oxy}acetamide;2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)acetamide;dBET1,inhibit,PROTACs,Epigenetic Reader Domain,Inhibitor,dBET 1,dBET-1;JQ1-Thalidomide conjugate | | CAS: | 1799711-21-9 | | MF: | C38H37ClN8O7S | | MW: | 785.27 | | EINECS: | | | Product Categories: | | | Mol File: | 1799711-21-9.mol |  |
| | dBET1 Chemical Properties |
| Melting point | 186 - 187°C | | density | 1.55±0.1 g/cm3(Predicted) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 10.68±0.40(Predicted) | | form | Solid | | color | Pale Yellow | | Stability: | Hygroscopic |
| | dBET1 Usage And Synthesis |
| Description | dBET1 is a PROTAC compound comprised of BET bromodomain antagonist (+)-JQ1 linked to a cereblon E3 ubiquitin ligase ligand. | | Uses | dBET1 induces highly selective cereblon-dependent BET protein degradation in vitro and in vivo as well as delays leukemia progression in mice. | | storage | Store at -20°C |
| | dBET1 Preparation Products And Raw materials |
|